HM Payson & Co. lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.4% during the first quarter, Holdings Channel reports. The institutional investor owned 28,176 shares of the company’s stock after selling 400 shares during the period. HM Payson & Co.’s holdings in Eli Lilly and were worth $2,370,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. First Command Financial Services Inc. increased its position in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares in the last quarter. Heritage Trust Co purchased a new position in shares of Eli Lilly and during the first quarter valued at $135,000. Point72 Asia Hong Kong Ltd increased its position in shares of Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares in the last quarter. Penserra Capital Management LLC increased its position in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares in the last quarter. Finally, Crestwood Advisors Group LLC purchased a new position in shares of Eli Lilly and during the first quarter valued at $179,000. 75.59% of the stock is currently owned by institutional investors and hedge funds.

Shares of Eli Lilly and Company (NYSE:LLY) traded up 0.17% during midday trading on Wednesday, reaching $81.85. 548,764 shares of the company traded hands. The firm has a market capitalization of $86.35 billion, a PE ratio of 35.42 and a beta of 0.34. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72. The stock has a 50 day moving average price of $82.77 and a 200 day moving average price of $81.92.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter last year, the firm posted $0.86 EPS. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. Analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.55%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.

TRADEMARK VIOLATION WARNING: “HM Payson & Co. Has $2.37 Million Position in Eli Lilly and Company (LLY)” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.watchlistnews.com/hm-payson-co-has-2-37-million-position-in-eli-lilly-and-company-lly/1495885.html.

Several brokerages have weighed in on LLY. BidaskClub raised shares of Eli Lilly and from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. Barclays PLC lifted their price target on shares of Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Tuesday, July 4th. BMO Capital Markets reaffirmed a “sell” rating and set a $73.00 price target on shares of Eli Lilly and in a report on Friday, August 4th. Berenberg Bank reaffirmed a “buy” rating and set a $100.00 price target on shares of Eli Lilly and in a report on Thursday, July 27th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $96.00 price target (up previously from $93.00) on shares of Eli Lilly and in a report on Thursday, July 13th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $88.27.

In other Eli Lilly and news, VP Michael J. Harrington sold 22,833 shares of the firm’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the completion of the sale, the vice president now directly owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the sale, the insider now directly owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The disclosure for this sale can be found here. Insiders sold a total of 669,733 shares of company stock valued at $55,845,287 over the last ninety days. Corporate insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.